Tevard Biosciences
@TevardB
Followers
221
Following
163
Media
38
Statuses
91
Joined November 2020
Hear our co-founder and leader Daniel Fischer on how ‘recovering what’s lost in translation’, is central to our approach to gene therapy to restore vital protein production and deliver life-changing therapies for rare diseases caused by nonsense mutations.
Daniel Fischer of @TevardB discusses his journey as the parent of a child with a rare disease, how it led to his co-founding Tevard, and its pursuit of tRNA therapies that may treat a range of diseases with a single medicine. @GlobalGenes #RARECast.
0
0
0
Register now and don’t miss this session at @GlobalGenes RARE Drug Development Symposium where our CEO Daniel Fischer will join a panel to discuss:. 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗠𝗼𝗱𝗮𝗹𝗶𝘁𝗶𝗲𝘀 & 𝗧𝗵𝗲𝗶𝗿 𝗥𝗲𝗹𝗲𝘃𝗮𝗻𝗰𝗲 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗗𝗶𝘀𝗲𝗮𝘀𝗲.
0
0
1
🚀Congrats to Teerith Pasricha, Victoria Rose, Sophia Zheng, Viggo Blomquist and Steffany Villasenor who are “graduating” from Tevard to pursue PhDs! Thanks for the visit from Tevard co-founder/mentor Harvey Lodish. Excited to see what they’ll do next!
0
0
2
🧬 Happy tRNA Day!. We’re pioneering tRNA-based therapies to fix nonsense mutations—restoring full-length protein function and offering hope for patients with rare genetic diseases once thought untreatable. Small molecule, big impact!
0
0
2
In @Nature, our CEO Daniel Fischer--father to a child with a rare disease--shares what drives Tevard:. "I know we're working with cell lines and mice, but we're working for kids--and I have one at home.". 🧬 Read:
These parents set up biotechnology companies, hoping to cure their children's illnesses.
0
0
2
👏 Thanks to @edsilverman and @statnews for highlighting our new CSO, Elisabeth Gardiner. We’re excited to have her join us to advance our tRNA platform to cure rare genetic diseases. 🚶♀️ Learn more about Elisabeth here: #tRNA #RareDisease.
statnews.com
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
0
0
2
🧬Exciting data from the 2025 RNA Therapeutics conference!. Tevard's Julien Oury, PhD shared compelling preclinical results showing suppressor tRNAs restored up to 34% dystrophin & improved muscle function in a DMD model. 🔬 No off-target effects observed.
1
0
6
Today is International #DravetSyndromeAwarenessDay. A rare form of epilepsy, Dravet begins in infancy and impacts individuals for life. Our founders have deep personal ties to Dravet; in fact, our company is named for the mission of reversing Dravet (spelled backward is Tevard).
0
0
3
Pleased to present at mRNA Horizons: Investor Summit for Breakthroughs in Medicine on June 24 (10AM–5PM), hosted by @mRNAAlliance with astr partners + @BrownRudnickLLP. Exciting day ahead with top innovators + investors in mRNA!. #mRNAHorizons #biotech #lifesciences
0
0
2
Excited to welcome Dr. Elisabeth Gardiner to the team as our new Chief Scientific Officer! . Her expertise will be instrumental as we advance our lead program targeting TTN-related dilated cardiomyopathy (data expected soon!) and we expand our pipeline.
0
0
2
Director of Research at @TevardBio, Peter Eimon will present at #CureDuchenne #2025FUTURES: data show up to 27% restoration of full-length dystrophin in a #DMD model, sustained for 12+ weeks with no adverse effects.
0
0
6
Data at #ASGCT2025 showed suppressor tRNA therapy restored full-length dystrophin up to 27% in a #Duchenne (DMD) model. Durable and potent efficacy and improved behavioral outcomes without observable side effects across multiple muscles demonstrated.
0
0
6
Tevard is excited to commemorate Rare Disease Month with our fellow Lilly Gateway Labs community members this February! #RareDiseaseDay
0
0
2
November is National Epilepsy Awareness Month! At Tevard, we're advancing therapies to cure genetic diseases, including epilepsy. Visit @EpilepsyFdn to learn about this year's theme - #ShareYourPurplePower and get involved: #NEAM2024
0
0
3
We look forward to attending the @EpilepsyFdn Pipeline Conference to discuss the latest advancements in epilepsy treatments. If you're attending, catch our presentation on September 26 to learn more about our pioneering approach to develop tRNA therapeutics. #biotechnology
0
0
1
At Tevard, we're devoted to improving the lives of people with severe genetic diseases like Duchenne muscular dystrophy (DMD). In honor of #WorldDuchenneAwarenessDay, learn more about DMD, and see how you can help raise awareness: #WDAD24
0
1
2
We're looking forward to the upcoming RNA Leaders USA Congress. Tevard CEO, Daniel Fisher, will give a presentation on our work to pioneer novel tRNA therapeutics and how our platform is enabling us to advance our pipeline. See the full agenda: #RNALeaders
0
1
3
We're thrilled to move our HQ to Lilly Gateway Labs! Being selected to join @EliLillyCo's innovation hub demonstrates the ability of our tRNA platform & potential of our programs in neurological, cardiac, and muscular disorders. Learn more: #biotech
0
0
2
We welcome industry veteran and RNA therapeutics expert John Maraganore, founding CEO of Alnylam, as Strategic Advisor and Board Observer.
tevard.reportablenews.com
Industry Veteran and RNA Therapeutics Expert, John Maraganore, Joins Tevard Biosciences as Strategic Advisor and Board Observer
0
1
3
Join Greg Robinson, Tevard's Chief Scientific Officer, at Cure Duchenne's Futures conference in Orlando as he discusses our work in developing novel tRNA-based therapies to treat Duchenne Muscular Dystrophy. #CureDuchenne #CureDuchenneFutures #tRNA #RareDiseas
0
0
0